Recent developments include management changes with new appointments for President and CFO, a licensing agreement granting ASK Pharma Greater China rights to AN9025, and notable trading activity reflected in market coverage.

• Adlai Nortye appointed Dr. Archie Tse as President and Dr. Ye as Chief Financial Officer effective April 1, 2026, with the prior President retiring but remaining as Corporate Strategy Professor [S2].
• In December 2025, the company granted ASK Pharma exclusive Greater China rights to develop and commercialize the pan-RAS inhibitor AN9025, with potential payments up to approximately $230 million USD including upfront, milestone, and royalty payments [N7].
• The company’s ADSs have been noted as among the most active in after-hours and pre-market trading sessions in late 2025 and early 2026 [N6][N8].
• Recent market commentary highlights Adlai Nortye as outperforming or outpacing other medical stocks in 2026 [N3][N4][N1].
• An RSI alert indicated that Adlai Nortye (ANL) was oversold as of March 2026 [N2].
• The company recognized $5.0 million in revenue in 2025 from contract liability related to a non-refundable upfront fee from a customer for licensing rights [S1].

The company’s focus on RAS-targeting therapies and innovative immunotherapies addresses significant unmet medical needs in oncology. Its licensing deal with ASK Pharma for Greater China rights to AN9025 provides a potential revenue stream through upfront, milestone, and royalty payments. The recent private placement financing enhances liquidity to support ongoing R&D and operational activities. Management changes with experienced executives in leadership roles may strengthen strategic execution. The company’s dual presence in the U.S. and China offers access to broad markets and scientific expertise [N7][N5][S1][S2].

Adlai Nortye Ltd. faces risks typical of clinical-stage biopharmaceutical companies, including the uncertainty of clinical trial outcomes, regulatory approvals, and the ability to generate product revenue. The company has reported significant net losses and negative cash flows, requiring continued financing to sustain operations. Dependence on collaborations and licensing agreements introduces execution risks. Management transitions may pose short-term operational challenges. The company’s Cayman Islands holding structure and exposure to PRC tax and regulatory environments add complexity and potential risks [S1][S2].

Adlai Nortye Ltd.'s moat is primarily based on its specialized pipeline targeting difficult-to-treat cancers through novel RAS inhibitors and next-generation immunotherapies. The company’s dual R&D presence in the U.S. and China provides access to diverse scientific talent and regulatory environments. Its intellectual property portfolio, including patents and licenses for its drug candidates, supports competitive positioning. Strategic collaborations, such as the licensing agreement with ASK Pharma for Greater China rights, enhance its commercialization potential. However, as a clinical-stage company without approved products, its moat is contingent on successful clinical development and regulatory approvals [S1].

• Clinical and Regulatory Risk: The company’s drug candidates are in clinical or preclinical stages, and there is uncertainty regarding successful trial outcomes and regulatory approvals.
• Financial Risk: The company has incurred significant net losses and negative cash flows, requiring additional financing to support operations and R&D activities.
• Execution Risk: Dependence on collaborations, licensing agreements, and management transitions may affect the company’s ability to execute its business plans effectively.
• Market and Competitive Risk: The oncology therapeutics market is highly competitive, with rapid technological changes and competing products that may impact the company’s commercial prospects.
• Regulatory and Tax Risk: The company operates under a Cayman Islands holding structure with subsidiaries in the U.S. and China, exposing it to complex tax and regulatory environments, including potential PRC tax residency determinations.

• Adlai Nortye Ltd. is a global clinical-stage biopharmaceutical company focused on discovering and developing innovative cancer therapies with dual R&D presence in the U.S. and China.
• The company’s pipeline focuses on two key areas: RAS-targeting therapies (including AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC) and next-generation cancer immunotherapies (including AN8025, a tri-functional fusion protein, and AN4005, an oral small-molecule PD-L1 inhibitor).
• As of December 31, 2024, the company had cash and cash equivalents of approximately $60.9 million USD and a current ratio of 1.41, indicating liquidity above current liabilities.
• The company reported revenue of $5.0 million USD in 2025, primarily from recognizing contract liability related to a non-refundable upfront fee from a customer for licensing rights.
• Net losses have been reported for recent years: approximately $109.2 million in 2023, $51.9 million in 2024, and $35.5 million in 2025, reflecting ongoing investment in R&D and operations.
• Research and development expenses decreased from $58.2 million in 2023 to $32.8 million in 2025, reflecting a shift from clinical to preclinical stages and reduced CRO service fees.
• Administrative expenses decreased from $15.3 million in 2023 to $8.3 million in 2025, partly due to lower share-based compensation expenses.
• In December 2025, Adlai Nortye granted ASK Pharma exclusive Greater China rights to develop and commercialize the pan-RAS inhibitor AN9025, with potential payments up to approximately $230 million USD including upfront, milestone, and royalty payments.
• In February 2026, the company announced a private placement expected to raise gross proceeds of approximately $140 million USD before fees, supporting liquidity and operations.
• Management changes include the appointment of Dr. Archie Tse as President and Dr. Ye as Chief Financial Officer effective April 1, 2026, with the prior President retiring but remaining as Corporate Strategy Professor.
• The company operates primarily through subsidiaries in the U.S. and China, with a Cayman Islands holding company structure.
• The company’s financial statements are prepared under IFRS and include critical accounting estimates related to R&D capitalization and share-based payments.
• The company faces risks typical of clinical-stage biopharmaceutical firms, including regulatory approval, clinical trial outcomes, financing needs, and intellectual property protection.
• The company has a cybersecurity risk management program overseen by management and the board, with no material cybersecurity incidents reported in 2024.
• The company’s ADSs are listed on the Nasdaq Global Market and are considered readily tradeable securities in the U.S.
• The company’s liquidity as of December 31, 2024, included $60.9 million in cash and cash equivalents, current assets of $64.1 million, and current liabilities of $45.4 million, yielding a cash ratio of 1.34.